FindTrial
Sign In

A phase 2 study of capecitabine (R340) in patients who have failed previous treatment with taxane for metastatic breast cancer.

A phase 2 study of capecitabine (R340) in patients who have failed previous treatment with taxane for metastatic breast cancer.

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220019
Enrollment
Unknown
Registered
2005-09-01
Start date
2005-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

investigational material(s) Generic name etc : R340 (capecitabine) INN of investigational material : Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Females 2. 20 and over Age and below 75 3. performance status 0-2, 4. Patients with a history of at least one regimen of chemotherapy including taxene (paclitaxel or docetaxel) (including (neo-) adjuvant therapy)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
objective response rate, time to response, duration of response, time to disease progression, overall survival, response rate stratified by previous treatment, safety profile—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026